Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1017

Next Previous
Search
Trial Profile

A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1017

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evunzekibart (Primary)
  • Indications Adenoid cystic carcinoma; Advanced breast cancer; Anal cancer; Cancer; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Alligator Bioscience

    • Most Recent Events

    • 29 Jan 2025 According to Alligator Biosciences media release, the clinical data from this trial has been published in the Journal for ImmunoTherapy of Cancer (JITC).
    • 11 Jul 2024 According to Alligator Biosciences media release, data published in the journal Cancer Immunology, Immunotherapy in October 2023.
    • 21 Apr 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top